This inventor holds 5 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 2 EPO patents. Top assignees: National Institute of Health and Medical Research, Assistance Publique - Hopitaux De Paris (Aphp), Universite Dé Lorraine. Active years: 2013-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Paris, FR (2013 - 2020)
- Charenton-le-Pont, FR (2017 - 2021)
Company Filing History:
5 out of 1,853 
3 out of 77 
2 out of 93 
Years Active: 2013-2024
Title: Innovator Spotlight: Hafid Ait-Oufella - Pioneering Cardiovascular Disease Treatment
Introduction:
Hafid Ait-Oufella, a distinguished inventor based in Charenton-le-Pont, France, has made significant contributions to the field of cardiovascular disease prevention and treatment. With a notable portfolio of four patents, Ait-Oufella's work has the potential to revolutionize the way we approach heart health.
Latest Patents:
Among his latest innovations are methods and kits for predicting the risk of cardiovascular diseases. By measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) in a subject's sample and comparing it to a reference level, Ait-Oufella's invention identifies individuals at risk and provides tailored therapies. Additionally, his work on administering agents capable of depleting CD8 T cells shows promise in treating myocardial infarction by reducing necrosis and limiting post-ischemic left ventricular remodeling.
Career Highlights:
Ait-Oufella has been associated with prestigious institutions such as Inserm, the French National Institute of Health and Medical Research, and Universite De Lorraine. His expertise and dedication have led to groundbreaking advancements in the field of cardiovascular medicine, garnering international recognition for his impactful research.
Collaborations:
Throughout his career, Ait-Oufella has collaborated with esteemed colleagues, including Sebastien Gibot and Amir Boufenzer. These partnerships have fueled interdisciplinary approaches to tackling complex cardiovascular challenges, fostering a culture of innovation and collaboration within the scientific community.
Conclusion:
In conclusion, Hafid Ait-Oufella's pioneering work in cardiovascular disease prevention and treatment signifies a remarkable milestone in medical innovation. His dedication to improving patient outcomes and advancing scientific knowledge underscores his status as a visionary inventor at the forefront of cutting-edge research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile